The present study revealed that as much as 98% of the bone metastases in patients with NSCLC harboring EGFR mutation after treatment with gefitinib responded to show osteosclerotic change, and 51% of patients achieved CR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.